Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Saved in:
| Title: | Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression. |
|---|---|
| Authors: | Rivera FB; Department of Medicine, Lincoln Medical Center, New York, NY, USA., Cha SW; Cebu Institute of Medicine, Cebu City, Philippines., Magalong JV; College of Medicine, San Beda University, Manila, Philippines., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Arias-Aguirre E; Cebu Institute of Medicine, Cebu City, Philippines., Aguirre Z; Cebu Institute of Medicine, Cebu City, Philippines., Varona MC; Cebu Institute of Medicine, Cebu City, Philippines., Co EMF; Cebu Institute of Medicine, Cebu City, Philippines., Lumbang GNO; Cebu Institute of Medicine, Cebu City, Philippines., Enkhmaa B; Division of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA. |
| Source: | Current medical research and opinion [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1103-1121. Date of Electronic Publication: 2024 Jun 11. |
| Publication Type: | Journal Article; Meta-Analysis |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
